Review Reports
- Neha Tyagi 1,
- Manish Rathi 2 and
- Chendil Damodaran 1,*
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe reviewed paper, Manuscript ID: pharmaceutics-4495794, outlines a method to screen for natural products which are toxic to prostate cancer cells. More specifically, they developed a luminescent marker which quantitatively shows the presence of a truncated form of the androgen receptor. This alternatively spliced version of the AR is transported to the nucleus in the absence of ligand binding. They used this method to do a multi-tiered screening of a natural product library, which after additional screening of further fractionated extracts found several compounds which are toxic to two prostate cancer cell lines and have minimal toxicity in normal prostate epithelial cells. The screening method was then applied to an additional natural product library, also finding several extracts which are toxic to the same two prostate cancer cell line.
Overall, the methodological decisions were well reasoned and explained in the manuscript. Below are comments for specific findings and lines in the manuscript:
- The introduction makes strong case for screening natural compounds for the ability to target the N-terminal domain of AR.
- In figure 3 D more half of the 13 subfractions at 1.25 ug/mL were greater than 50% viability of 22Rv1 cells. I thought the cut-off was 90% inhibition (10% viability) at 1.25mg/mL.
- In figure 4A, the AR and AR-V7 are very weak in the blot image, and the actin is very low relative to the other lanes on the same blot. This sample shouldn’t be used for the plot of relative expression fold change. The resulting graph shows that h5 yielded the largest reduction of AR, AR-V7 and PSA. The results text should state that this particular protein sample had a much lower level of protein than the others, so the normalization to actin may not be appropriate.
- Line 363: The authors note the “significant down regulation of both full-length AR and AR-V7, …” This should be qualified by adding "....mRNA".
- Line 374-375: The purified subfractions inhibit growth of both PC cell lines. The extracts from which the puffed components were isolated were shown to have low toxicity in normal prostate cells. However, after purification of individual compounds, they are at a higher molar concentration which could be toxic to normal cells. I and some other readers may wonder if this compound at higher molar concentration compared to the more crude extract, is still not toxic to non-tumor prostate cells.
- If this screening is leading to a potential therapeutic which would be taken systemically, it is important that candidate drugs are not toxic to cells types other than prostate epithelial cells. This is not to say that cell lines from each organ should be tested, but toxicity tests with 1 or 2 more cell lines would tell more about the candidate compounds toxicity. This limitation is sufficiently addressed in the Limitations section.
- Figure 5 G: the qPCR data shows very impressive downregulation of AR, AR-V7, PSA mRNAs after treatment with isolitsealiicolide C for 6 hours.
- The results section on the validation of the 22RV1-HiBiT screening strategy (Figure 6) could benefit from showing more of the data in the supplemental data file. There were 8 hits that were confirmed in two cell lines, yet only two of them were shown in the figure. It will be of interest to the readers what the dose-dependency of the other 6 fractions looks like in the two lines. Also they could show the lack of toxicity in the RWPE-1 cells.
Author Response
Please see the attachment.
Author Response File:
Author Response.docx
Reviewer 2 Report
Comments and Suggestions for AuthorsThis manuscript presents a high-throughput screening workflow for identifying natural product fractions that suppress AR-V7 signaling in castration-resistant prostate cancer. The authors combine a HiBiT–AR-V7 reporter system with cell viability assays, biochemical validation, subfractionation, and chemical characterization. The workflow is technically sound and was further validated using an expanded marine-derived fraction library. The identification of isolitsealiicolide C and isolinderanolide B further demonstrates its utility. Overall, the study is well organized, supported by substantial experimental data, and should be of interest to readers of Pharmaceutics. A few minor points should be clarified before publication.
- Please provide clearer statistical information for the quantitative data, including the number of biological replicates, statistical tests used, definition of error bars, and significance criteria where applicable.
- Please clarify the hit-selection criteria (≥90% inhibition, ≤10% inhibition in RWPE-1 cells, and z-score >3) in the Methods and indicate whether these thresholds were predefined or determined during assay optimization.
- Please consider moderating some of the mechanistic claims, as the current data support suppression of AR/AR-V7 signaling and induction of apoptosis, while the detailed downstream mechanism remains to be fully established.
Author Response
Please see the attachment.
Author Response File:
Author Response.docx